Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA Transfers Perindopril Franchise Rights to Symplmed

Jul 03, 2013 9:00am EDT

XOMA to Present at the JMP Securities Healthcare Conference

Jul 02, 2013 4:06pm EDT

XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program for Gevokizumab

Jun 25, 2013 9:00am EDT

XOMA Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma Gangrenosum

Jun 13, 2013 9:00am EDT

XOMA Highlights Recent Achievements and Reports Financial Results for First Quarter 2013

May 08, 2013 4:01pm EDT

XOMA to Present at Credit Suisse 2013 Antibody Day

May 06, 2013 2:30pm EDT

XOMA to Announce First Quarter 2013 Financial Results and Host Webcast on May 8

Apr 25, 2013 8:01am EDT

XOMA Announces Clinical Study Investigating Gevokizumab in Patients With Non-Infectious Anterior Scleritis Has Opened for Enrollment at the National Eye Institute

Apr 10, 2013 8:00am EDT

XOMA Appoints Tom Klein to Newly Created Position of Chief Commercial Officer

Mar 18, 2013 1:00pm EDT

XOMA Reports 2012 Operational Highlights and Fourth Quarter and Full-Year Financial Results

Mar 12, 2013 4:05pm EDT
RSS
  • Prev
    • 1...
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • ...43
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2023 XOMA Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2023 XOMA • Powered by GeneratePress
    Scroll back to top